Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours ยท Estimated delivery Aug 14 - Aug 19
FDA approved Gilead's twice-yearly lenacapavir, marketed as Yeztugo , for HIV pre-exposure prophylaxis on June 18, 2025, based on the PURPOSE 1 and PURPOSE 2 trial program, which Gilead describes as demonstrating superiority "among a broad and geographically diverse range of cisgender men and gender-diverse people" ( [111] )
Interestingly, the treatment demonstrated dose-dependent therapeutic effects, with moderate dosages proving more effective than high doses (1,000 mg/kg), possibly due to pharmacodynamic principles, where excessive concentrations saturate biological pathways and diminish therapeutic outcomes (Tyagi et al., 2025
For prescription use only
By addressing the underlying hormonal and metabolic factors that influence mood, SynergenX helps patients regain balance, confidence, and a stronger sense of self
US$ 29.07
US$ 29.18
US$ 24.72
